Press Releases

Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Norditropin^® FlexPro^®, a new prefilled growth hormone injection pen to be used by children and adults.

Norditropin^® FlexPro^® has a unique new dosing mechanism, a user-friendly design which makes it easy to learn and use, and an audible click that confirms that the dose has been delivered. Norditropin^® FlexPro^® requires no reconstitution and no loading of cartridges. Norditropin^® FlexPro^® is available in 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml pens.

In a handling study^[1], 100% of patients found it easy to learn how to use Norditropin^® FlexPro^®. Ninety-nine percent of patients found it easy to push the button to dose, and 97% felt confident the correct dose was delivered.

“During our 20 years providing Norditropin^® growth hormone, we have listened to patients and we understand the importance of providing simple, hassle-free patient care,” says Pablo de Mora, global vice president of Growth Hormone Treatment in Novo Nordisk. “With the advantages of our new Norditropin^® FlexPro^® we are convinced that daily injections will be made even simpler, so patients are better able to achieve their individual treatment goals.”

Novo Nordisk introduced Norditropin^® in 1988; the first liquid growth hormone formulation, Norditropin^® SimpleXx^®, in 1999; and the first prefilled growth hormone pen, Norditropin NordiFlex^®, in 2004. The introduction of Norditropin^® FlexPro^® represents the latest advance in growth hormone pens building on this heritage.

For photographs relating to this press release please visit novonordisk.com – Media

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Further information:

[1] Fuchs GS et al. Clin Ther 2009; 31 (12)